Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5594
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma ; volume:39 ; number:38 ; day:19 ; month:8 ; year:2020 ; pages:6113-6128 ; date:9.2020
Oncogene ; 39, Heft 38 (19.8.2020), 6113-6128, 9.2020
- Creator
-
Ruan, Hailong
Li, Sen
Bao, Lin
Zhang, Xiaoping
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41388-020-01409-6
- URN
-
urn:nbn:de:101:1-2023021021070105254734
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ruan, Hailong
- Li, Sen
- Bao, Lin
- Zhang, Xiaoping
- SpringerLink (Online service)
Other Objects (12)
Metastatic collecting duct carcinoma of the kidney treated with sunitinib
Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
Ipotiroidismo indotto da sunitinib
Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib
Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma
Sunitinib-Induced Acute Liver Failure
Sunitinib nei feocromocitomi e paragangliomi
Metastatic collecting duct carcinoma of the kidney treated with sunitinib
Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
Ipotiroidismo indotto da sunitinib
Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib
Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma
Sunitinib-Induced Acute Liver Failure
Sunitinib nei feocromocitomi e paragangliomi
Metastatic collecting duct carcinoma of the kidney treated with sunitinib
Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
Ipotiroidismo indotto da sunitinib
Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib
Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma
Sunitinib-Induced Acute Liver Failure